Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Open Access
- 18 November 2020
- journal article
- review article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 7 (4) , 741-757
Abstract
Injection-site pain (ISP) is a subjective side effect that is commonly reported with the subcutaneous administration of biological agents, yet it may only be a concern to some. Multiple factors related to the product formulation, such as pH, volume and excipients, and/or to the injection process have the potential to contribute to ISP, while patient-related factors, such as low body weight, gender and age, can make an individual more susceptible to experiencing ISP. While total elimination of ISP remains unlikely with any subcutaneously administered agent, it can be minimised by helping the patient to develop a confident and competent injection technique via robust and effective training. Careful management of patient expectations along with open discussion regarding the potential risk of ISP may serve to minimise treatment-related anxieties and, importantly, allow the patient to remain in control of his/her treatment. Other interventions to help minimise ISP include psychological interventions, allowing biologics to reach room temperature prior to injection, using the most suitable injection device for the individual patient and selecting an alternative drug formulation, when available. Productive patient–physician communication remains important in order to support and optimise treatment experience and adherence, while also providing the opportunity for patients to discuss any ISP-related issues.Keywords
Funding Information
- Biogen International GmbH
This publication has 89 references indexed in Scilit:
- The role of excess subcutaneous fat in pain and sensory sensitivity in obesityEuropean journal of pain, 2013
- Selective TNF-α inhibitor-induced injection site reactionsExpert Opinion on Drug Safety, 2013
- Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS studyBMC Neurology, 2012
- An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjectsBMC Neurology, 2011
- Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)Health and Quality of Life Outcomes, 2011
- Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative studyJournal of Neurology, 2010
- A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney diseaseCurrent Medical Research and Opinion, 2008
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Pain following controlled cutaneous insertion of needles with different diametersSomatosensory & Motor Research, 2006